Sangamo Therapeutics Q4 EPS $(0.11) Misses $(0.06) Estimate, Sales $14.200M Miss $16.475M Estimate

Sangamo Therapeutics reported a Q4 EPS of $(0.11), missing the analyst estimate of $(0.06) by 83.33%. The company's quarterly sales were $14.200 million, falling short of the $16.475 million estimate by 13.81%, although this represents an 88.05% increase from $7.551 million in the same period last year.